Lipum AB Logo

Lipum AB

Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.

LIPUM | ST

Overview

Corporate Details

ISIN(s):
SE0015660899 (+1 more)
LEI:
549300V7JL0004BHBD93
Country:
Sweden
Address:
Tvistevägen 48 C, 907 36 Umeå
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a first-in-class humanized antibody that offers a unique mechanism of action by targeting the protein bile salt-stimulated lipase (BSSL). Lipum's primary goal is to address unmet medical needs and improve the quality of life for patients suffering from conditions such as rheumatoid arthritis (RA). The company has successfully completed its First-in-Human (FIH) Phase I clinical trial for SOL-116, with findings supporting continued development towards a potential new therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lipum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lipum AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lipum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-14 Peter Hovstadius Other Sell 2,000 28,260.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 22,770.00 SEK
2025-04-14 Peter Hovstadius Other Sell 1,500 21,030.00 SEK

Peer Companies

Company Country Ticker View
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.